SAFETY PHARMACOLOGY GLP VALIDATION DATA REVIEW WEBINAR
Register now to watch the 10-minute video presentation on demand!
Get A Sneak Preview Of Sinclair Research's Safety Pharmacology Validation Data!
In this 10-minute video presentation on demand, Dr. Michael R. Gralinski, CEO of CorDynamics, reviews the results of 3 safety pharmacology validation studies that were conducted in 2020 in Sinclair Research's purpose-built telemetry facility to validate GLP Safety Pharmacology service offerings.
Three pharmacological validation studies were conducted in telemetered dogs using well characterized hemodynamic, electrocardiographic, and respiratory positive controls. All three studies demonstrated ability to detect expected effects of positive controls with a high degree of fidelity.
Three pharmacological validation studies were conducted:
Validation Study #1: Hemodynamics: Verapamil (0, 1.5, 15 mg/kg)
Validation Study #2: Respiratory: Doxapram (0, 1.5, 4 mg/kg)
Validation Study #3: Electrocardiography and arrhythmias: Dofetilide (0, 0.1, 0.3 mg/kg)
About the Presenter:
Dr. Michael R. Gralinski is Chief Executive Officer and Co-founder of CorDynamics, a cardiovascular contract research organization based in Chicago. Dr. Gralinski has extensive experience in pharmaceutical development, including product safety, toxicology and safety pharmacology. He is a Past-President of the Safety Pharmacology Society and holds a B.S. in Pharmacology and Toxicology from the University of Wisconsin-Madison and a Ph.D. in Pharmacology (Cardiovascular) from the University of Michigan.